In recent years, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, reshaping traditional therapeutic strategies. Among them, PD-1/PD-L1 pathway inhibitors have achieved remarkable clinical success across multiple cancer types. As PD-(L)1 inhibitor therapies mature, pharmaceutical leaders are now focusing on PD-(L)1 bispecific antibodies (BsAbs)—a next-generation...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)